Prostate Cancer Clinical Test and Statistic
Larger-volume tumors of the prostate are common among older men. Available tests for the early detection of cancer have limited specificity, which necessitates a relatively high biopsy rate. The positive predictive value of combined digital rectal examination and PSA measurement has been defined, but the negative predictive value is less clear. Measurement of PSA is the most sensitive noninvasive test for prostate cancer. However, digital rectal
examination detects cancer that would otherwise be missed by PSA measurement.
Clinical trials serve as one way of finding prostate cancer cures. All prostate cancer medications must take pass the three phases required to gain approval from the Food and Drug Administration.
Phase I of the clinical trials test the safety of a new drug. The second clinical phase is designed to determine how the proposed new prostate cancer treatment works. Patients are given the drug in high doses during this phase.
The patients are watched to see what effect the test drug has on their prostate cancer. The final phase of clinical trial testing pits test medications against standard treatments. A control group is given dosages of the test drug while a second group uses standard methods of medicine-with the effects documented
The purpose of the trial is to test the safety and effectiveness of the technique, called high intensity focused ultrasound (HIFU), as the initial treatment in men with newly-diagnosed, localized prostate cancer.
Undiagnosed prostate cancer is highly prevalent, especially among older men [42-49]. Although many of these cancers may be considered incidental, evidence suggests that consideration of screening is warranted because earlier diagnosis of clinically significant cancers often has the potential to improve outcome [10, 12]. In fact, prostate cancer is so common among older men that selecting subpopulations for screening on the basis of risk factors other than age, such as race or family history, would not be necessary if screening and treatment strategies that favorably affect outcome were available.
examination detects cancer that would otherwise be missed by PSA measurement.
Clinical trials serve as one way of finding prostate cancer cures. All prostate cancer medications must take pass the three phases required to gain approval from the Food and Drug Administration.
Phase I of the clinical trials test the safety of a new drug. The second clinical phase is designed to determine how the proposed new prostate cancer treatment works. Patients are given the drug in high doses during this phase.
The patients are watched to see what effect the test drug has on their prostate cancer. The final phase of clinical trial testing pits test medications against standard treatments. A control group is given dosages of the test drug while a second group uses standard methods of medicine-with the effects documented
The purpose of the trial is to test the safety and effectiveness of the technique, called high intensity focused ultrasound (HIFU), as the initial treatment in men with newly-diagnosed, localized prostate cancer.
Undiagnosed prostate cancer is highly prevalent, especially among older men [42-49]. Although many of these cancers may be considered incidental, evidence suggests that consideration of screening is warranted because earlier diagnosis of clinically significant cancers often has the potential to improve outcome [10, 12]. In fact, prostate cancer is so common among older men that selecting subpopulations for screening on the basis of risk factors other than age, such as race or family history, would not be necessary if screening and treatment strategies that favorably affect outcome were available.